Equity Overview
Price & Market Data
Price: $0.259
Daily Change: -$0.0088 / 3.39%
Daily Range: $0.256 - $0.279
Market Cap: $326,745,600
Daily Volume: 2,649,735
Performance Metrics
1 Week: 8.01%
1 Month: -0.25%
3 Months: -11.28%
6 Months: -13.55%
1 Year: 10.36%
YTD: -13.55%
Company Details
Employees: 13
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.